(Q28323156)

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

29 October 2022

author name string

E. H. Heinonen

1

1 reference

Europe PubMed Central

PubMed publication ID

1686954

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1686954

29 October 2022

R. Lammintausta

2

1 reference

Europe PubMed Central

PubMed publication ID

1686954

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1686954

full work available at URL

29 October 2022

language of work or name

English

0 references

publication date

1991

0 references

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0404.1991.tb05020.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0404.1991.tb05020.x/fullpdf

29 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Acta neurologica Scandinavica. Supplementum

29 October 2022

published in

0 references

volume

136

0 references

page(s)

44-59

0 references

cites work

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

5

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Clinical chemistry of monoamine oxidase.

29 October 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications

29 October 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

On the mode of action of L-deprenyl in the human central nervous system

29 October 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem

29 October 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons

29 October 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Histochemical localisation of monoamine oxidase A and B in rat brain

29 October 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Ageing, monoamines, and monoamine-oxidase levels.

29 October 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of age on the activity and molecular properties of human brain monoamine oxidase

29 October 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer's type by means of large cryosection autoradiography: a pilot study.

29 October 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine oxidase -A and -B activity in the rat brain after hemitransection

29 October 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The active centers of monoamine oxidase types "A" and "B": binding with (14C)-clorgyline and (14C)-deprenyl

29 October 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The possible mechanisms of action of (-)deprenyl in Parkinson's disease.

29 October 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Dopamine oxidation and its inhibition by (-)-deprenyl in man

29 October 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?

29 October 2022

22

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment

29 October 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

29 October 2022

24

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease

29 October 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy

29 October 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Cumulative effects of irreversible MAO inhibitors in vivo

29 October 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects

29 October 2022

29

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Dose regimen of deprenyl (selegiline) and platelet MAO activities

29 October 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use

29 October 2022

32

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl

29 October 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Recovery of MAO-B enzyme activity after (-)deprenyl (selegiline) pretreatment, measured in vivo

29 October 2022

35

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

29 October 2022

36

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain

29 October 2022

39

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma

29 October 2022

40

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition

29 October 2022

42

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl

29 October 2022

43

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier

29 October 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

(-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function

29 October 2022

46

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats

29 October 2022

48

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of repeated treatment with brofaromine, moclobemide and deprenyl on α1-adrenergic and dopaminergic receptors in the rat brain

29 October 2022

50

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Selegiline as a primary treatment of Parkinson's disease

29 October 2022

51

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effect of deprenyl on the progression of disability in early Parkinson's disease

29 October 2022

52

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

29 October 2022

53

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation

29 October 2022

54

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Serotonin-mediated behavior in rats chronically treated with (-) deprenyl

29 October 2022

56

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

29 October 2022

57

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine oxidase inhibitors and L-dopa

29 October 2022

58

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects

29 October 2022

59

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenyl as symptomatic therapy in Parkinson's disease

29 October 2022

61

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Selegiline in the treatment of Parkinson's disease

29 October 2022

62

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

29 October 2022

Parkinson's disease

64

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism

29 October 2022

65

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

On tyramine, food, beverages and the reversible MAO inhibitor moclobemide

29 October 2022

67

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

HYPERTENSIVE CRISIS DUE TO MONOAMINE-OXIDASE INHIBITORS

29 October 2022

68

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Absence of "cheese effect" during deprenyl therapy: some recent studies.

29 October 2022

69

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine

29 October 2022

70

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat

29 October 2022

71

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl

29 October 2022

72

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of various MAO-B inhibitors on rabbit arterial strip response to tyramine

29 October 2022

73

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena

29 October 2022

75

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

29 October 2022

76

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Tyramine pressor sensitivity changes during deprenyl treatment

29 October 2022

77

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment

29 October 2022

79

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Tyramine studies and the safety of MAOI drugs

29 October 2022

80

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor

29 October 2022

82

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Does phenylethylamine cause schizophrenia?

29 October 2022

83

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Analysis and the effects of some drugs on the metabolism of phenylethylamine and phenylacetic acid

29 October 2022

85

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of β-phenylethylamine on central and peripheral monoamine-containing neurons

29 October 2022

86

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

2-phenylethylamine and methamphetamine enhance the spinal monosynaptic reflex by releasing noradrenaline from the terminals of descending fibers

29 October 2022

87

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Phenylethylamine: evidence for a direct, postsynaptic dopamine-receptor stimulating action

29 October 2022

88

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of -phenethylamine upon spontaneous motor activity in mice: a dual effect on locomotor activity

29 October 2022

91

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS

29 October 2022

93

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Amphetamine, p-hydroxyamphetamine and β-phenethylamine in mouse brain and urine after (−)- and (+)-deprenyl administration

29 October 2022

94

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

29 October 2022

95

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors

29 October 2022

97

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

L-deprenyl plus L-phenylalanine in the treatment of depression

29 October 2022

98

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture

29 October 2022

99

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

MPTP toxicity: implications for research in Parkinson's disease

29 October 2022

100

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease

29 October 2022

101

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

29 October 2022

102

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

29 October 2022

103

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

29 October 2022

104

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

29 October 2022

105

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.

29 October 2022

106

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey

29 October 2022

107

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.

29 October 2022

108

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

29 October 2022

109

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain

29 October 2022

110

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine oxidase B(MAO-B) is the major catalyst for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation in human brain and other tissues.

29 October 2022

111

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death.

29 October 2022

112

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

29 October 2022

113

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues.

29 October 2022

114

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Evidence for neuromelanin involvement in MPTP-induced neurotoxicity

29 October 2022

115

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+

29 October 2022

116

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

29 October 2022

117

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion

29 October 2022

118

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease

29 October 2022

119

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Mitochondrial complex I deficiency in Parkinson's disease

29 October 2022

120

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

29 October 2022

122

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse

29 October 2022

123

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Neuropathological changes in the caudate nucleus elicited by MPTP and their prevention by monoamine oxidase inhibition

29 October 2022

124

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.

29 October 2022

125

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives

29 October 2022

127

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

29 October 2022

128

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine

29 October 2022

129

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment

29 October 2022

130

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment?

29 October 2022

131

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Epidemiologic study of Parkinson's disease in Hong Kong

29 October 2022

132

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Environmental factors and Parkinson's disease: a case-control study in China

29 October 2022

133

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition

29 October 2022

134

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

29 October 2022

136

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age

29 October 2022

137

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Hydrogen peroxide production by rat brain in vivo

29 October 2022

140

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Parkinson's disease: a disorder due to nigral glutathione deficiency?

29 October 2022

141

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Glutathione peroxidase activity in Parkinson's disease brain.

29 October 2022

142

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Brain Peroxidase and Catalase in Parkinson Disease

29 October 2022

143

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease

29 October 2022

144

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

29 October 2022

145

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains

29 October 2022

146

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Brain iron and ferritin in Parkinson's and Alzheimer's diseases.

29 October 2022

147

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

29 October 2022

148

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Intramitochondrial formation of oxidized glutathione during the oxidation of benzylamine by monoamine oxidase

29 October 2022

149

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

29 October 2022

151

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

29 October 2022

152

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease.

29 October 2022

153

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effect of selective monoamine oxidase inhibitors on the morphine-induced hypothermia in restrained rats

29 October 2022

154

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Maintenance on L-deprenyl prolongs life in aged male rats

29 October 2022

156

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

29 October 2022

157

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The effect of selective MAO inhibitors on the conditioned avoidance response of Wistar rats

29 October 2022

158

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The pharmacology of selegiline ((-)deprenyl). New aspects

29 October 2022

159

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

29 October 2022

161

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

29 October 2022

163

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

29 October 2022

164

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine-oxidase inhibitors and prolactin secretion

29 October 2022

166

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine

29 October 2022

171

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Apomorphine, deprenyl, and yohimbine fail to increase sexual behavior in rhesus males

29 October 2022

173

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Monoamine oxidase B inhibition reduces gastric mucosal blood flow, basal acid secretion, and cold water restraint-induced gastric mucosal injury in rats

29 October 2022

175

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness

29 October 2022

177

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Possible interactions between deprenyl and prozac.

29 October 2022

178

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice

29 October 2022

180

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Interaction of selective inhibitors of monoamine oxidase with pethidine in rabbits

29 October 2022

181

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Role of brain monoamines in the fatal hyperthermia induced by pethidine or imipramine in rabbits pretreated with a monoamine oxidase inhibitor

29 October 2022

182

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Severe adverse interaction between pethidine and selegiline

29 October 2022

183

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Fatal hyperpyrexia after withdrawal of levodopa

29 October 2022

186

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

"On-off"-induced lethal hyperthermia

29 October 2022

187

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Chromatographic studies on the binding, action and metabolism of (-)-deprenyl

29 October 2022

190

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

29 October 2022

191

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency

29 October 2022

192

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Pharmacokinetics and metabolism of selegiline

29 October 2022

193

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

29 October 2022

194

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Stereochemistry: a source of problems in medicinal chemistry

29 October 2022

195

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa

29 October 2022

196

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Postmortem tissue methamphetamine concentrations following selegiline administration

29 October 2022

197

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues

29 October 2022

199

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

In vivo monoamine oxidase inhibition by d-amphetamine

29 October 2022

201

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Mechanism of the adverse interaction between monoamine oxidase inhibitors and amphetamine

29 October 2022

202

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Behavioral characterization of d- and l-amphetamine: neurochemical implications

29 October 2022

203

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

A comparison of d-amphetamine, l-amphetamine, and methamphetamine self-administration in rhesus monkeys.

29 October 2022

204

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effect of enantiomers of deprenyl (selegiline) and amphetamine on physical abuse liability and cortical electrical activity in rats.

29 October 2022

205

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

l-Deprenyl in atypical depressives.

29 October 2022

207

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Amphetamines in the treatment of Parkinson's disease

29 October 2022

208

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Amphetamine-stimulated release of endogenous dopamine from the rat caudate nucleus in vivo.

29 October 2022

209

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties

29 October 2022

210

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats

29 October 2022

212

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.1991.TB05020.X

29 October 2022

Identifiers